Milan Anadkat is a Dermatology physician affiliated with Barnes-Jewish Hospital. OpenAlex indexes 142 publications with 3,543 citations (h-index 30); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4901 Forest Park Ave
Div Im Dermatology, Ste 502
Saint Louis, MO 631081495
Telephone
314-273-3376Registry record last updated 15 Apr 2025.
Clinical trials
- Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
Sponsor: Spectrum Pharmaceuticals, Inc
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year20253 payments$10,305openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20253 payments
- Boehringer Ingelheim International GmbHProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
30.8%Tetracycline-class Drug10.7%Doxycycline Hyclate87%Doxycycline Monohydrate13%Part D<11 patientsAzole Antifungal8.6%Ketoconazole100%Part D≥64 patients+ 5 more classes in this area
Dermatology
26%Corticosteroid14.7%Triamcinolone Acetonide82%Triamcinolone acetonide19%Part D + Part B≥105 patientsInterleukin-4 Receptor alpha Antagonist4.8%Dupixent Pen72%Dupixent Syringe28%Part D<11 patients+ 3 more classes in this area
Sensory organs
18.9%Corticosteroid17.6%Clobetasol Propionate60%Hydrocortisone26%Betamethasone Dipropionate7%Dexamethasone7%Part D<11 patientsAminoglycoside Antibacterial1.3%Gentamicin Sulfate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Pamela Woodard, MD
Barnes-Jewish Hospital
Tsuyoshi Kaneko, MD
Barnes-Jewish Hospital
Sidharth Puram, MD
Barnes-Jewish Hospital
Iskra Pusic, MD
Barnes-Jewish Hospital
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”